ANGO

AngioDynamics Inc. (ANGO) | Rumor.io

AngioDynamics

ANGO

Attention (50-day avg)0%

Attention rank (50-day avg)#4,108

Bullish sentiment (50-day avg)100%

Price to earnings ratio41.4

Market capitalization642.3M

Earnings per share-0.88

Dividend yield (TTM)—

Revenue (annual)320.2M

Net income (annual)-36.7M

Social

What share of all stock conversation is about ANGO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Jul 23

The current price of ANGO is $13.82, with a 2.81% decline.
Many individuals are holding ANGO at a loss, with some feeling "crushed" and "underwater".
The current market sentiment towards ANGO is overwhelmingly negative, with multiple users expressing feelings of pain, suffering, and being alone in their losses.

Generated by AI

Sentiment

Of the messages about ANGO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.59% -8.18
Bearish	—	—	—	9.41% +8.18

Bullish· Jan 6

AngioDynamics reported a "clean" beat-and-raise quarter, with adjusted EBITDA nearly doubling YoY to $5.9M, driven by strict cost discipline and unexpected strength in its legacy Medical Device segment.
The company raised its full-year sales outlook after strong Q2 results and a narrower loss, with revenue beating expectations and losses improving, and management citing market share gains as a key driver of momentum.
AngioDynamics' Q2 revenue and EPS beat expectations, with the company posting 8.8% revenue growth driven by MedTech innovations, and raising guidance for fiscal 2026, reflecting confidence in sustained profitability.

Bearish· Mar 30

AngioDynamics' (ANGO) Q3 results missed revenue estimates and the company lowered its FY23 guidance.
The company's FY23 sales outlook was cut to $338-342M, down from prior guidance of $342-348M, and consensus of $342M.
ANGO's stock price declined by 27% after the company's guidance cut, with the stock also hitting a new 52-week low.

Generated by AI

Topics

Of the messages about ANGO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	29.71%
Analysts	—	—	—	15.78%
Earnings	—	—	—	31.03%
Macro	—	—	—	19.63%
Technical Analysis	—	—	—	3.85%
Controversies	—	—	—	0%

Earnings· Jan 6

AngioDynamics (ANGO) reported Q2 FY26 earnings, beating estimates with adjusted EPS of $0.00 and revenue of $79.4M.
The company raised its full-year guidance, with revenue expected to be $312-314M and EPS expected to be -$0.33 to -$0.23.
AngioDynamics' strong Med Tech momentum drove profitability, with Auryon, AlphaVac, and NanoKnife gaining share across key markets.

Announcements· Jan 6

AngioDynamics (ANGO) beat Q2 FY26 estimates, raised full-year guidance, and posted strong FDA progress, but the stock dropped 14% on leadership transition news.
The company reported a revenue beat, with $79.4M in sales, and a narrower Q2 loss, with management citing market share gains as driving momentum.
AngioDynamics raised its full-year sales outlook after strong Q2 results, with analysts seeing 63% upside, and the company's MedTech innovations driving sustained profitability.

Generated by AI

Community

Of the messages about ANGO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	16.67%	16.67%	16.67%	25.36%
Newcomers	83.33%	83.33%	83.33%	74.64%

Regulars· Jan 6

AngioDynamics reported Q2-26 results with adj. EPS of $0.00, revenue of $79.4M, and a net loss of $6.4M, citing strong Med Tech momentum.
The company raised its FY2026 sales and adjusted EBITDA forecast, and CEO Jim Clemmer plans to retire in FY2027, with shares rising 8% after the announcement.
AngioDynamics beat revenue expectations and narrowed its Q2 loss, with management citing market share gains and strong momentum in the Med Tech sector.

Newcomers· Jul 23

Many users are experiencing losses with ANGO, with prices down by 2.81% to $13.82.
Some users are feeling crushed or miserable due to holding ANGO at a loss.
Several users are wondering if they are the only ones suffering or underwater with ANGO.

Generated by AI

LATHAM, N.Y., September 28, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2027 before the market open on Thursday, October 8, 2026. The Company’s management will host a conference call at 8:00 am ET the same day to discuss the results.

1d agoYahoo Finance Australia

AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

1mo agoYahoo Finance

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

AngioDynamics (NASDAQ:ANGO) expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and toward higher-growth medical technology platforms, executives said during a Canaccord fireside chat

1mo agoYahoo Finance

AngioDynamics at Canaccord Genuity conference: growth pivot deepens

1mo agoInvesting.com

AngioDynamics, Inc. (ANGO) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow

1mo agoSeeking Alpha

AngioDynamics, Inc. (ANGO) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow (NASDAQ:ANGO) 2026-08-11

2026-08-11. The following slide deck was published by AngioDynamics, Inc.

1mo agoSeeking Alpha

Also Discussed

Investors talking about ANGO also mention

#	Name	Attention
1	RPM International Inc.RPM	0%0
2	PriceSmart, Inc.PSMT	0%new
3	Lindsay CorporationLNN	0%-0.02
4	GNTY - Guaranty Bancshares, Inc.	——
5	Richardson Electronics, Ltd.RELL	0%0
6	Home BancShares, Inc.HOMB	0%0
7	Acuity Brands IncAYI	0%-0.02
8	Edwards Lifesciences CorporationEW	0%new
9	AAR Corp.AIR	0%new
10	WD-40 CompanyWDFC	0%new

AngioDynamics Inc.

Healthcare
Medical Instruments & Supplies

AngioDynamics Inc. is a medical technology company that develops, manufactures, and markets minimally invasive medical devices for healthcare providers. Its product portfolio supports image-guided procedures across vascular intervention, vascular access, oncology, and surgical care, with devices used to treat peripheral vascular disease and other non-coronary conditions. The company offers a broad range of therapeutic and diagnostic products, including atherectomy systems, venous therapies, ablation technologies, fluid management tools, dialysis access products, drainage devices, and angiographic accessories. AngioDynamics serves hospitals, health systems, ambulatory procedure sites, and specialist physicians, primarily in the United States, with additional international sales through distributors and direct channels. Headquartered in Latham, New York, AngioDynamics plays a specialized role in the medical device market by providing tools designed for minimally invasive treatment and procedural precision.

Website

Location

14 Plaza Drive

Latham, NY, 12110

United States

Social

What share of all stock conversation is about ANGO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Jul 23

The current price of ANGO is $13.82, with a 2.81% decline.
Many individuals are holding ANGO at a loss, with some feeling "crushed" and "underwater".
The current market sentiment towards ANGO is overwhelmingly negative, with multiple users expressing feelings of pain, suffering, and being alone in their losses.

Generated by AI

Sentiment

Of the messages about ANGO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.59% -8.18
Bearish	—	—	—	9.41% +8.18

Bullish· Jan 6

AngioDynamics reported a "clean" beat-and-raise quarter, with adjusted EBITDA nearly doubling YoY to $5.9M, driven by strict cost discipline and unexpected strength in its legacy Medical Device segment.
The company raised its full-year sales outlook after strong Q2 results and a narrower loss, with revenue beating expectations and losses improving, and management citing market share gains as a key driver of momentum.
AngioDynamics' Q2 revenue and EPS beat expectations, with the company posting 8.8% revenue growth driven by MedTech innovations, and raising guidance for fiscal 2026, reflecting confidence in sustained profitability.

Bearish· Mar 30

AngioDynamics' (ANGO) Q3 results missed revenue estimates and the company lowered its FY23 guidance.
The company's FY23 sales outlook was cut to $338-342M, down from prior guidance of $342-348M, and consensus of $342M.
ANGO's stock price declined by 27% after the company's guidance cut, with the stock also hitting a new 52-week low.

Generated by AI

Topics

Of the messages about ANGO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	29.71%
Analysts	—	—	—	15.78%
Earnings	—	—	—	31.03%
Macro	—	—	—	19.63%
Technical Analysis	—	—	—	3.85%
Controversies	—	—	—	0%

Earnings· Jan 6

AngioDynamics (ANGO) reported Q2 FY26 earnings, beating estimates with adjusted EPS of $0.00 and revenue of $79.4M.
The company raised its full-year guidance, with revenue expected to be $312-314M and EPS expected to be -$0.33 to -$0.23.
AngioDynamics' strong Med Tech momentum drove profitability, with Auryon, AlphaVac, and NanoKnife gaining share across key markets.

Announcements· Jan 6

AngioDynamics (ANGO) beat Q2 FY26 estimates, raised full-year guidance, and posted strong FDA progress, but the stock dropped 14% on leadership transition news.
The company reported a revenue beat, with $79.4M in sales, and a narrower Q2 loss, with management citing market share gains as driving momentum.
AngioDynamics raised its full-year sales outlook after strong Q2 results, with analysts seeing 63% upside, and the company's MedTech innovations driving sustained profitability.

Generated by AI

Community

Of the messages about ANGO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	16.67%	16.67%	16.67%	25.36%
Newcomers	83.33%	83.33%	83.33%	74.64%

Regulars· Jan 6

AngioDynamics reported Q2-26 results with adj. EPS of $0.00, revenue of $79.4M, and a net loss of $6.4M, citing strong Med Tech momentum.
The company raised its FY2026 sales and adjusted EBITDA forecast, and CEO Jim Clemmer plans to retire in FY2027, with shares rising 8% after the announcement.
AngioDynamics beat revenue expectations and narrowed its Q2 loss, with management citing market share gains and strong momentum in the Med Tech sector.

Newcomers· Jul 23

Many users are experiencing losses with ANGO, with prices down by 2.81% to $13.82.
Some users are feeling crushed or miserable due to holding ANGO at a loss.
Several users are wondering if they are the only ones suffering or underwater with ANGO.

Generated by AI

AngioDynamics

Social

Jul 23

Bullish· Jan 6

Bearish· Mar 30

Earnings· Jan 6

Announcements· Jan 6

Regulars· Jan 6

Newcomers· Jul 23

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

AngioDynamics at Canaccord Genuity conference: growth pivot deepens

AngioDynamics, Inc. (ANGO) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow

AngioDynamics, Inc. (ANGO) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow (NASDAQ:ANGO) 2026-08-11

Also Discussed

AngioDynamics Inc.

Company Information

Location

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

AngioDynamics at Canaccord Genuity conference: growth pivot deepens

AngioDynamics, Inc. (ANGO) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow

AngioDynamics, Inc. (ANGO) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow (NASDAQ:ANGO) 2026-08-11

Also Discussed

Social

Jul 23

Bullish· Jan 6

Bearish· Mar 30

Earnings· Jan 6

Announcements· Jan 6

Regulars· Jan 6

Newcomers· Jul 23